Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, open label, single arm study is to evaluate MTX110 for the treatment of Diffuse Intrinsic Pontine Glioma

Next Previous
X
Search
Trial Profile

A Phase II, open label, single arm study is to evaluate MTX110 for the treatment of Diffuse Intrinsic Pontine Glioma

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 12 Jun 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Panobinostat (Primary)
  • Indications Diffuse intrinsic pontine glioma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms GlioKIDS

    • Most Recent Events

    • 16 May 2023 According to Biodexa Pharmaceuticals, 20-F filing, Midatech has changed its name to Biodexa Pharmaceuticals
    • 17 Jun 2021 According to a Midatech media release, the company expects to initiate this Phase II study in DIPG later this year.
    • 31 Mar 2020 According to a Midatech media release, because of a technicality, the EU has not yet confirmed Midatech's status as an SME, a prerequisite for grant eligibility. The trial may be cancelled if the EU grant is not received.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top